SCEMBLIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SCEMBLIX (SCEMBLIX).
Selective inhibitor of BCR-ABL1 tyrosine kinase, targeting the myristoyl pocket (STAMP) to induce inactive conformation of BCR-ABL1, including T315I mutant.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6; minor contribution from CYP2C8, CYP2C9, and CYP2C19. |
| Excretion | Primarily fecal (77%) with minor renal excretion (11%). Biliary excretion contributes to fecal elimination; <1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life approximately 21–23 hours (range 10–35 h). Supports once-daily dosing. |
| Protein binding | Approximately 97% bound to plasma proteins (primarily albumin and alpha-1 acid glycoprotein). |
| Volume of Distribution | Apparent Vd of 1320 L (≈18.9 L/kg for 70 kg). Extensive tissue distribution. |
| Bioavailability | Absolute bioavailability not established; oral absorption is rapid with peak plasma concentrations at 2–5 h. High-fat meal decreases Cmax by 30% and AUC by 25%. |
| Onset of Action | Oral administration: BCR-ABL1 inhibition occurs within hours; clinical response (e.g., hematologic improvement) typically evident within 2–4 weeks. |
| Duration of Action | Trough concentrations maintain target inhibition over 24 h with once-daily dosing. Continuous therapy required for sustained response. |
200 mg orally once daily with a meal.
| Dosage form | TABLET |
| Renal impairment | For GFR ≥60 mL/min: no adjustment. For GFR 30-59 mL/min: reduce dose to 100 mg once daily. For GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 100 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required; monitor renal function more frequently due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SCEMBLIX (SCEMBLIX).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Because of potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for one week after last dose. M/P ratio not available. |
| Teratogenic Risk | In animal studies, SCEMBLIX (asciminib) caused embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below the human exposure at the recommended dose. There are no adequate and well-controlled studies in pregnant women. Based on mechanism of action, may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. First trimester: highest risk for major malformations. Second and third trimesters: risk of fetal growth restriction and adverse effects on fetal development. |
■ FDA Black Box Warning
None.
| Serious Effects |
None.
| Precautions | ["Cardiovascular adverse reactions (arrhythmias, hypertension)","Pancreatitis","Fluid retention (pleural effusion, pericardial effusion)","Hepatotoxicity","Myelosuppression","Embryo-fetal toxicity"] |
Loading safety data…
| Fetal Monitoring | Monitor for myelosuppression with complete blood counts every two weeks for the first three months, then monthly. Monitor pancreatic enzymes (lipase and amylase) every four weeks. Monitor blood pressure and heart rate at baseline and periodically. Assess for signs of bleeding, infection, and fluid retention. In pregnancy, monitor fetal growth by ultrasound if exposure occurs. |
| Fertility Effects | Based on animal studies, SCEMBLIX may impair female and male fertility. In male rats, reduced sperm count and motility observed at clinically relevant exposures. In female rats, reduced fertility and increased preimplantation loss. Reversibility not established. |